Who buys Product and Service Code AN13 (Health R&D Services; Health Care Services; Experimental Development), who wins it, what's open now and which contracts expire next — from FY2026 USAspending awards and live SAM.gov solicitations.
Contract data as of Oct 18, 2026 (USAspending) · recent coverage verified weekly
| Quarter | Awards | Obligated | Change |
|---|---|---|---|
| Q1 FY2026 | 2 | $1.4M | — |
| Q2 FY2026 | 14 | $13.6M | +850% |
| Q3 FY2026 | 8 | $181.1M | +1228% |
| Q4 FY2026 | 22 | $65.9M | -64% |
Federal fiscal quarters (Q1 = Oct–Dec). Awards are counted in the quarter they start; obligations are the award's obligated amount.
| # | Contractor | Obligated | Share |
|---|---|---|---|
| 1 | SHIONOGI & COMPANY LIMITED | $156.1M | 59.6% |
| 2 | SCYNEXIS INC | $18.5M | 7.0% |
| 3 | FLOWWELL MEDICAL LLC | $15.0M | 5.7% |
| 4 | OXOS MEDICAL INC | $9.6M | 3.7% |
| 5 | BATTELLE MEMORIAL INSTITUTE | $9.4M | 3.6% |
| 6 | ISOLA THERAPEUTICS INC | $7.5M | 2.9% |
| 7 | SNC THERAPEUTICS, INC. | $7.0M | 2.7% |
| 8 | LOVELACE BIOMEDICAL RESEARCH INSTITUTE | $3.7M | 1.4% |
| 9 | MORPHOSIS INC | $3.5M | 1.3% |
| 10 | PHYSICAL SCIENCES INC. | $3.5M | 1.3% |
Registrations are rolled up to their corporate parent (USAspending parent UEI), so a company with several SAM registrations ranks once.
| Agency | Obligated | Share |
|---|---|---|
| Department of Health and Human Services | $220.1M | 84.0% |
| Department of the Interior | $36.6M | 14.0% |
| Department of Veterans Affairs | $4.1M | 1.6% |
| Department of Defense | $1.3M | 0.5% |
| Start | Contract · recipient | Obligated |
|---|---|---|
| Sep 15, 2026 | ADVANCE THE DEVELOPMENT OF SCY-247, A NOVEL ANTIFUNGAL CURRENTLY IN PHASE 1 CLINICAL TRIALS, FOR THE TREATMENT OF INVASIVE CANDIDIASIS AND PROPHYLAXIS OF INVASIVE FUNGAL DISEASE AS ORAL AND IC FORMULA SCYNEXIS INC · Department of Health and Human Services | $18.5M |
| Sep 29, 2026 | DEVELOP AND VALIDATE THE OXOS X3, A PORTABLE X-RAY SYSTEM DESIGNED TO TRANSFORM TRAUMA RESPONSE BY BRINGING HOSPITAL-GRADE IMAGING DIRECTLY TO THE POINT OF NEED. THIS EFFORT WILL ELIMINATE CRITICAL TR OXOS MEDICAL INC · Department of Health and Human Services | $9.6M |
| Aug 21, 2026 | RTOR BIO-AMT-2311: ADVANCED DEVELOPMENT AND VALIDATION OF ASSAYS TO ASSESS FILOVIRUS INFECTION IN NONHUMAN PRIMATES BATTELLE MEMORIAL INSTITUTE · Department of Health and Human Services | $6.8M |
| Aug 26, 2026 | RTOR BIO-AMT-2312: ASSESSMENT OF THE THERAPEUTIC POTENTIAL OF CHLOROQUINE AND OSELTAMIVIR IN TWO (2) LETHAL MODELS OF INFLUENZA A H5N1 LOVELACE BIOMEDICAL RESEARCH INSTITUTE · Department of Health and Human Services | $3.7M |
| Aug 27, 2026 | MORPHOSIS INC. PHASE II BASE MORPHOSIS INC · Department of the Interior | $3.5M |
The largest obligations on awards that started in the window’s latest quarter.
| Ends | Contract · recipient | Obligated |
|---|---|---|
| Sep 29, 2027 | IGF::OT::IGF REGENERON PHARMACEUTICALS INC · Department of Health and Human Services | $695.7M |
| Sep 25, 2027 | IGF::OT::IGF - REGENERON OTHER TRANSACTION AUTHORITY (OTA) AWARD REGENERON PHARMACEUTICALS INC · Department of Health and Human Services | $278.8M |
| Mar 31, 2027 | CERUS - DEVELOPMENT AND IMPLEMENTATION OF PATHOGEN REDUCTION TECHNOLOGY (PRT). IGF::OT::IGF CERUS CORPORATION · Department of Health and Human Services | $185.2M |
| Dec 31, 2026 | CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS OLIVE BIOSCIENCES INC. · Department of Health and Human Services | $73.9M |
| May 31, 2027 | CLINICAL TRIALS AND INFORMATION MANAGEMENT SUPPORT THE EMMES COMPANY, LLC · Department of Health and Human Services | $51.1M |
45 contracts under this code reach their final end date (options included) in the next 12 months.
| Set-aside type | Obligated | Share |
|---|---|---|
| Small business set-aside | $33.7M | 14.6% |
| 8(a) | $0 | 0.0% |
| SDVOSB | $1.5M | 0.6% |
| WOSB / EDWOSB | $0 | 0.0% |
| HUBZone | $0 | 0.0% |
| No set-aside (full & open) | $195.8M | 84.7% |
Share of obligations on awards whose set-aside type is recorded — 88% of this market's dollars. Most USAspending bulk-archive records leave the field blank, so blank awards are excluded rather than counted as full & open.
Showing the 10 most recently posted of 95. Links open the notice on SAM.gov.
Source: USAspending.gov contract awards (prime awards with a start date from Oct 1, 2025 through Sep 30, 2026), SAM.gov contract opportunities, and SBA size standards. Recompetes are contracts whose final end date — options included — falls in the next 12 months. Figures are recomputed when a new USAspending load lands. See our data sources.